{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:29:28Z","timestamp":1786321768988,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI157155"],"award-info":[{"award-number":["R01 AI157155"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI181103"],"award-info":[{"award-number":["U19 AI181103"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI181103"],"award-info":[{"award-number":["U19 AI181103"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74762-x","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:33:02Z","timestamp":1782581582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice"],"prefix":"10.1038","volume":"17","author":[{"given":"Chieh-Yu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Scheaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-5511","authenticated-orcid":false,"given":"James Brett","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9206-1975","authenticated-orcid":false,"given":"Igor P.","family":"Dmitriev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2413-0937","authenticated-orcid":false,"given":"Yuhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer Kumar","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6914-125X","authenticated-orcid":false,"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-8590","authenticated-orcid":false,"given":"Sean P. J.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3802-6014","authenticated-orcid":false,"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6129-2532","authenticated-orcid":false,"given":"Ali H.","family":"Ellebedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-3165","authenticated-orcid":false,"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"74762_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100529","volume":"3","author":"VV Edara","year":"2022","unstructured":"Edara, V. V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep. Med. 3, 100529 (2022).","journal-title":"Cell Rep. Med."},{"key":"74762_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41392-023-01447-y","volume":"8","author":"J Hern\u00e1ndez","year":"2023","unstructured":"Hern\u00e1ndez, J. et al. Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273. Signal Transduct. Target. Ther. 8, 174 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"74762_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00528-24","volume":"98","author":"N Soudani","year":"2024","unstructured":"Soudani, N. et al. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters. J. Virol. 98, e0052824 (2024).","journal-title":"J. Virol."},{"key":"74762_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286.e278 (2023).","journal-title":"Cell"},{"key":"74762_CR5","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","volume":"28","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2\/3 trial. Nat. Med. 28, 2388\u20132397 (2022).","journal-title":"Nat. Med."},{"key":"74762_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"74762_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1056\/NEJMc2214916","volume":"388","author":"J Zou","year":"2023","unstructured":"Zou, J. et al. Neutralization of BA.4\u2013BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N. Engl. J. Med. 388, 854\u2013857 (2023).","journal-title":"N. Engl. J. Med."},{"key":"74762_CR8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"C-Y Liang","year":"2024","unstructured":"Liang, C.-Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960 (2024).","journal-title":"Nature"},{"key":"74762_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41586-023-06025-4","volume":"617","author":"WB Alsoussi","year":"2023","unstructured":"Alsoussi, W. B. et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature 617, 592\u2013598 (2023).","journal-title":"Nature"},{"key":"74762_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36116","volume":"10","author":"J Favresse","year":"2024","unstructured":"Favresse, J. et al. Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)Variants 6 months after a homologous booster: is immunogenicity equivalent?. Heliyon 10, e36116 (2024).","journal-title":"Heliyon"},{"key":"74762_CR11","doi-asserted-by":"publisher","unstructured":"Pettini, E., Pastore, G., Fiorino, F., Medaglini, D. & Ciabattini, A. Short or long interval between priming and boosting: does it impact on the vaccine immunogenicity? Vaccines 9, https:\/\/doi.org\/10.3390\/vaccines9030289 (2021).","DOI":"10.3390\/vaccines9030289"},{"key":"74762_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMc2119426","volume":"386","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Effects of a prolonged booster interval on neutralization of Omicron variant. N. Engl. J. Med. 386, 894\u2013896 (2022).","journal-title":"N. Engl. J. Med."},{"key":"74762_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17259","volume":"9","author":"MA Prusinkiewicz","year":"2023","unstructured":"Prusinkiewicz, M. A. et al. Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2. Heliyon 9, e17259 (2023).","journal-title":"Heliyon"},{"key":"74762_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/vaccines13030263","volume":"13","author":"B Lu","year":"2025","unstructured":"Lu, B. et al. Impact of extended dosing intervals and ipsilateral versus contralateral boosting on mRNA vaccine immunogenicity in mice. Vaccines 13, 263 (2025).","journal-title":"Vaccines"},{"key":"74762_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMc2119912","volume":"386","author":"R Pajon","year":"2022","unstructured":"Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088\u20131091 (2022).","journal-title":"N. Engl. J. Med."},{"key":"74762_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156 (2024).","journal-title":"Nature"},{"key":"74762_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113 (2021).","journal-title":"Nature"},{"key":"74762_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","author":"D Laczk\u00f3","year":"2020","unstructured":"Laczk\u00f3, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53, 724\u2013732.e727 (2020).","journal-title":"Immunity"},{"key":"74762_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"74762_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","volume":"53","author":"K Lederer","year":"2020","unstructured":"Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity 53, 1281\u20131295.e1285 (2020).","journal-title":"Immunity"},{"key":"74762_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn5311","volume":"7","author":"M Kuraoka","year":"2022","unstructured":"Kuraoka, M. et al. Recall of B cell memory depends on relative locations of prime and boost immunization. Sci. Immunol. 7, eabn5311 (2022).","journal-title":"Sci. Immunol."},{"key":"74762_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jimmun\/vkae067","volume":"214","author":"L Burmas","year":"2025","unstructured":"Burmas, L. et al. Modulation of germinal center and antibody dynamics via ipsilateral versus contralateral immunization against SARS-CoV-2.  J. Immunol. 214, 335\u2013346 (2025).","journal-title":"J. Immunol."},{"key":"74762_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105103","volume":"103","author":"D Pattinson","year":"2024","unstructured":"Pattinson, D. et al. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses. EBioMedicine 103, 105103 (2024).","journal-title":"EBioMedicine"},{"key":"74762_CR24","doi-asserted-by":"publisher","first-page":"e00574","DOI":"10.1128\/jvi.00574-24","volume":"98","author":"B Ying","year":"2024","unstructured":"Ying, B. et al. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain. J. Virol. 98, e00574\u201300524 (2024).","journal-title":"J. Virol."},{"key":"74762_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113665","volume":"43","author":"W Jiang","year":"2024","unstructured":"Jiang, W. et al. Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization. Cell Rep. 43, 113665 (2024).","journal-title":"Cell Rep."},{"key":"74762_CR26","doi-asserted-by":"publisher","unstructured":"Ziegler, L. et al. Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination. eBioMedicine 95, https:\/\/doi.org\/10.1016\/j.ebiom.2023.104743 (2023).","DOI":"10.1016\/j.ebiom.2023.104743"},{"key":"74762_CR27","doi-asserted-by":"publisher","unstructured":"Dhenni, R. et al. Macrophages direct location-dependent recall of B cell memory to vaccination. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.04.005 (2025).","DOI":"10.1016\/j.cell.2025.04.005"},{"key":"74762_CR28","doi-asserted-by":"publisher","unstructured":"Fazli, S. et al. Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen. J. Clin. Investig. 134, https:\/\/doi.org\/10.1172\/JCI176411 (2024).","DOI":"10.1172\/JCI176411"},{"key":"74762_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e113 (2020).","journal-title":"Cell"},{"key":"74762_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109452","volume":"36","author":"AO Hassan","year":"2021","unstructured":"Hassan, A. O. et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 36, 109452 (2021).","journal-title":"Cell Rep."},{"key":"74762_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109400","volume":"36","author":"TL Bricker","year":"2021","unstructured":"Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021).","journal-title":"Cell Rep."},{"key":"74762_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","volume":"25","author":"M Gagne","year":"2024","unstructured":"Gagne, M. et al. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nat. Immunol. 25, 1913\u20131927 (2024).","journal-title":"Nat. Immunol."},{"key":"74762_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100230","volume":"2","author":"AO Hassan","year":"2021","unstructured":"Hassan, A. O. et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep. Med. 2, 100230 (2021).","journal-title":"Cell Rep. Med."},{"key":"74762_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995235","volume":"13","author":"P P\u00e9rez","year":"2022","unstructured":"P\u00e9rez, P. et al. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Front. Immunol. 13, 995235 (2022).","journal-title":"Front. Immunol."},{"key":"74762_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp1290","volume":"10","author":"TL Darling","year":"2024","unstructured":"Darling, T. L. et al. Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters. Sci. Adv. 10, eadp1290 (2024).","journal-title":"Sci. Adv."},{"key":"74762_CR36","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1080\/22221751.2022.2097479","volume":"11","author":"X Li","year":"2022","unstructured":"Li, X. et al. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerg. Microbes Infect. 11, 1890\u20131899 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"74762_CR37","doi-asserted-by":"publisher","unstructured":"Lin, Y. et al. Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2. J. Clin. Investig. 135, https:\/\/doi.org\/10.1172\/JCI175233 (2025).","DOI":"10.1172\/JCI175233"},{"key":"74762_CR38","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41590-025-02156-0","volume":"26","author":"DI Kwon","year":"2025","unstructured":"Kwon, D. I. et al. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice. Nat. Immunol. 26, 908\u2013919 (2025).","journal-title":"Nat. Immunol."},{"key":"74762_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","volume":"626","author":"K McMahan","year":"2024","unstructured":"McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385\u2013391 (2024).","journal-title":"Nature"},{"key":"74762_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27063-4","volume":"12","author":"D Lapuente","year":"2021","unstructured":"Lapuente, D. et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat. Commun. 12, 6871 (2021).","journal-title":"Nat. Commun."},{"key":"74762_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00912-1","volume":"9","author":"C Bissett","year":"2024","unstructured":"Bissett, C. et al. Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine. npj Vaccines 9, 118 (2024).","journal-title":"npj Vaccines"},{"key":"74762_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2523","volume":"378","author":"T Mao","year":"2022","unstructured":"Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).","journal-title":"Science"},{"key":"74762_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02250-23","volume":"15","author":"G Singh","year":"2024","unstructured":"Singh, G. et al. The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all Orthocoronavirinae genera. mBio 15, e0225023 (2024).","journal-title":"mBio"},{"key":"74762_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41590-025-02162-2","volume":"26","author":"GE Quirk","year":"2025","unstructured":"Quirk, G. E. et al. Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections. Nat. Immunol. 26, 829\u2013836 (2025).","journal-title":"Nat. Immunol."},{"key":"74762_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0025-6196(12)64949-0","volume":"63","author":"HY Reynolds","year":"1988","unstructured":"Reynolds, H. Y. Immunoglobulin G and its function in the human respiratory tract* *Based on a Medical Grand Rounds presentation at the Mayo Clinic, April 22, 1987. Mayo Clin. Proc. 63, 161\u2013174 (1988).","journal-title":"Mayo Clin. Proc."},{"key":"74762_CR46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","volume":"20","author":"M Yoshida","year":"2004","unstructured":"Yoshida, M. et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20, 769\u2013783 (2004).","journal-title":"Immunity"},{"key":"74762_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1128\/jcm.25.3.559-562.1987","volume":"25","author":"DK Wagner","year":"1987","unstructured":"Wagner, D. K. et al. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 25, 559\u2013562 (1987).","journal-title":"J. Clin. Microbiol."},{"issue":"Suppl 1","key":"74762_CR48","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s10875-012-9768-y","volume":"33","author":"T Rath","year":"2013","unstructured":"Rath, T. et al. The immunologic functions of the neonatal Fc receptor for IgG. J. Clin. Immunol. 33(Suppl 1), S9\u2013S17 (2013).","journal-title":"J. Clin. Immunol."},{"key":"74762_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371156","volume":"15","author":"K Togami","year":"2024","unstructured":"Togami, K. et al. Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium. Front. Immunol. 15, 1371156 (2024).","journal-title":"Front. Immunol."},{"key":"74762_CR50","doi-asserted-by":"publisher","first-page":"13751","DOI":"10.1073\/pnas.0912458109","volume":"109","author":"JH Kim","year":"2012","unstructured":"Kim, J. H., Davis, W. G., Sambhara, S. & Jacob, J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl. Acad. Sci. 109, 13751\u201313756 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74762_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110561","volume":"38","author":"BM Hauser","year":"2022","unstructured":"Hauser, B. M. et al. Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. Cell Rep. 38, 110561 (2022).","journal-title":"Cell Rep."},{"key":"74762_CR52","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41586-023-05715-3","volume":"615","author":"A Schiepers","year":"2023","unstructured":"Schiepers, A. et al. Molecular fate-mapping of serum antibody responses to repeat immunization. Nature 615, 482\u2013489 (2023).","journal-title":"Nature"},{"key":"74762_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj5129","volume":"6","author":"JE Oh","year":"2021","unstructured":"Oh, J. E. et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci. Immunol. 6, eabj5129 (2021).","journal-title":"Sci. Immunol."},{"key":"74762_CR54","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.4049\/jimmunol.173.6.4030","volume":"173","author":"WG Glass","year":"2004","unstructured":"Glass, W. G., Subbarao, K., Murphy, B. & Murphy, P. M. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice.  J. Immunol. 173, 4030\u20134039 (2004).","journal-title":"J. Immunol."},{"key":"74762_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-025-00800-5","volume":"11","author":"L You","year":"2025","unstructured":"You, L. et al. Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies. Cell Discov. 11, 49 (2025).","journal-title":"Cell Discov."},{"key":"74762_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114567","volume":"43","author":"A Muik","year":"2024","unstructured":"Muik, A. et al. Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1. Cell Rep. 43, 114567 (2024).","journal-title":"Cell Rep."},{"key":"74762_CR57","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","volume":"57","author":"MA Tortorici","year":"2024","unstructured":"Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904\u2013911.e904 (2024).","journal-title":"Immunity"},{"key":"74762_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc3582","volume":"5","author":"R Zang","year":"2020","unstructured":"Zang, R. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 5, eabc3582 (2020).","journal-title":"Sci. Immunol."},{"key":"74762_CR59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 28, 475\u2013485.e475 (2020).","journal-title":"Cell Host Microbe"},{"key":"74762_CR60","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1110656","volume":"308","author":"K Chandran","year":"2005","unstructured":"Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 1643\u20131645 (2005).","journal-title":"Science"},{"key":"74762_CR61","doi-asserted-by":"publisher","first-page":"8388","DOI":"10.1073\/pnas.92.18.8388","volume":"92","author":"SP Whelan","year":"1995","unstructured":"Whelan, S. P., Ball, L. A., Barr, J. N. & Wertz, G. T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. 92, 8388\u20138392 (1995).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74762_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jgm.1530","volume":"13","author":"S Roy","year":"2011","unstructured":"Roy, S. et al. Creation of a panel of vectors based on ape adenovirus isolates. J. Gene Med. 13, 17\u201325 (2011).","journal-title":"J. Gene Med."},{"key":"74762_CR63","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41590-024-01743-x","volume":"25","author":"B Ying","year":"2024","unstructured":"Ying, B. et al. Mucosal vaccine-induced cross-reactive CD8(+) T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. Nat. Immunol. 25, 537\u2013551 (2024).","journal-title":"Nat. Immunol."},{"key":"74762_CR64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","volume":"36","author":"JV Maizel Jr.","year":"1968","unstructured":"Maizel, J. V. Jr., White, D. O. & Scharff, M. D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115\u2013125 (1968).","journal-title":"Virology"},{"key":"74762_CR65","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","volume":"184","author":"F Amanat","year":"2021","unstructured":"Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936\u20133948.e3910 (2021).","journal-title":"Cell"},{"key":"74762_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.100","volume":"57","author":"D Stadlbauer","year":"2020","unstructured":"Stadlbauer, D. et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"74762_CR67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","volume":"604","author":"W Kim","year":"2022","unstructured":"Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74762-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74762-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74762-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:21Z","timestamp":1786320141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74762-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74762"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74762-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.D. is a consultant or advisor for Inbios, IntegerBio, Akagera Medicines, Moderna, Merck, and GlaxoSmithKline. The Diamond laboratory has received additional unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and IntegerBio. A.H.E. has received consulting and speaking fees from InBios International, Fimbrion Therapeutics, RGAX, Mubadala Investment Company, Moderna, Pfizer, GlaxoSmithKline, Danaher, Third Rock Ventures, Goldman Sachs and Morgan Stanley and is the founder of ImmuneBio Consulting. The Ellebedy laboratory has received funding from Moderna, Emergent BioSolutions, and AbbVie that is unrelated to the data presented in the current study. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8056"}}